Demeetra AgBio Announces It Can Produce Harm-Reduced Tobacco Products Through Gene Editing

 As FDA considers Cutting Nicotine in Cigarettes, Demeetra AgBio Announces It Can Produce Harm-Reduced Tobacco Products Through Gene Editing. Amid the FDA's confirmation it is considering a global reduction on nicotine in cigarettes to non- addictive levels, Demeetra AgBio, Inc., a pre-clinical therapeutics development, agbio, and genetic engineering company, announced today that its proprietary gene editing platform, Cas-CLOVER™ can be used to produce harm-reduced tobacco products and therapeutic cannabinoids in a feature with CRISPR Medicine News.

More:

prnewswire.com/news-releases/as-fda-considers-cutting-nicotine-in-cigarettes-demeetra-agbio-announces-it-can-produce-harm-reduced-tobacco-products-through-gene-editing-301313213.html